A Natural History Study is a prospective or retrospective observational study that systematically documents the course of a disease without therapeutic intervention. Its aim is to characterize the spontaneous disease pattern – onset, progression, complications, and outcome. Natural History Studies provide essential baseline data for clinical development, especially for rare diseases where historical control groups or external data are to be used for efficacy assessment. They often form the starting point for defining clinically relevant endpoints and estimating the natural progression rate.
Purpose and Applications
Natural History Studies are used in clinical research and drug development for various purposes:
- Baseline Data for Study Planning: Determining natural progression, endpoint variability, and event rates for sample size calculation in subsequent interventional studies.
- External Control Groups: In indications where a randomized control group is not feasible for ethical or practical reasons (e.g., rare pediatric diseases), Natural History Studies can serve as historical controls.
- Biomarker Identification: Characterizing disease course-associated biomarkers that could be suitable as prognostic or predictive markers for later studies.
- Patient Registries: Natural History Studies often form the basis for disease-specific registries that provide longitudinal data for regulators, reimbursement authorities, and the scientific community. These registries can serve as ongoing data infrastructure and fulfill post-market surveillance requirements after approval.
- Regulatory Evidence for Orphan Diseases: For rare diseases, the EMA and FDA accept Natural History Studies as supportive evidence in marketing authorization applications and for orphan drug classification. They provide proof that a disease is life-threatening or chronically debilitating, which is a prerequisite for orphan designation.
Study Design and Methodological Peculiarities
Natural History Studies can be designed as prospective or retrospective. Prospective studies allow for standardized data collection and uniform endpoint definitions but require long observation periods. Retrospective studies utilize existing clinical data (medical records, registries), can be conducted more quickly, but are more susceptible to data gaps and inconsistencies. Important methodological aspects include defining a clearly delineated patient cohort (inclusion and exclusion criteria), standardizing diagnostic time points and endpoint definitions, and controlling for selection and information bias. Since no randomization takes place, internal validity must be ensured through consistent bias management. Common sources of bias include selection bias in patient recruitment, information bias due to incomplete historical documentation, and survivorship bias if only patients who are still alive and receiving treatment are included. The use of standardized data collection instruments and prospective protocol registration minimizes these risks.
Regulatory Significance
The EMA has published specific guidelines for Natural History Studies as a source of evidence in rare diseases. In the context of orphan drugs, the EMA accepts well-documented Natural History Studies as an external control group if the following conditions are met: comparable patient populations, standardized data collection, pre-defined endpoints, and transparent documentation of the collection period. The BfArM and the G-BA also consider Natural History data in benefit assessments when no randomized data are available. In the USA, the FDA recognizes Natural History Studies as a valid source of evidence within the Rare Disease Program.
Relevance for clinical trials
Natural History Studies are a prerequisite for sound clinical development in rare diseases. Without solid data on the natural course of the disease, endpoints cannot be meaningfully chosen, sample sizes cannot be calculated, and the clinical benefit of a therapy cannot be convincingly presented to regulators and reimbursement authorities. Full-service CROs like mediconomics support sponsors in the planning, conduct, and regulatory-compliant documentation of Natural History Studies, including study protocols, ethics committee applications, data analysis for marketing authorization applications, and preparation of data for HTA submissions to the G-BA or NICE.
Frequently Asked Questions (FAQ)
Is a Natural History Study a clinical trial within the meaning of EU Regulation 536/2014?
No. A non-interventional Natural History Study, in which no intervention is performed on the patient, does not fall under EU Regulation No. 536/2014. However, it is subject to national data protection laws (GDPR), requirements for ethics committee review, and, if applicable, medical device law if diagnostic devices are used. Registry studies with active data collection generally require a positive ethics vote.
Can a Natural History Study replace a randomized control group?
Generally, not completely. Natural History Studies can be used as historical external controls in single-arm studies when randomization is unethical or practically impossible. In such cases, well-documented, methodologically high-quality Natural History data are often the only way to demonstrate efficacy at all. Regulatory acceptance depends on the quality of the data, the comparability of the populations, and the indication context. Regulators view external controls with critical distance and demand robust sensitivity analyses.
How does a Natural History Study differ from a patient registry?
Natural History Studies are prospective or retrospective research projects with pre-defined research questions, endpoints, and data collection periods. Patient registries are long-term database infrastructures that continuously collect data on patients with a specific disease. Natural History Studies can be based on registry data but are more specific in their objectives and time-limited.
Regulatory References
- EMA Guideline on the Use of Patient-Level Natural History Data to Support Drug Development in Rare Diseases (2021)
- ICH E8(R1) – General Considerations for Clinical Studies (2021): Observational Studies and Natural History
- EU Regulation (EU) 2016/679 (GDPR): Data Protection Requirements for Natural History Studies
- FDA Guidance: Considerations for the Design, Conduct, and Analysis of Observational Studies (2020)
- EMA Orphan Regulation (EC) No 141/2000: Natural History as a Basis for Orphan Drug Classification